Anti – PD 1 questions

Hi Mike, 

I cannot help you with number 2, but I can tell you that it is administered as an IV infusion.

All the best,

karen

Hi Mike, 

I cannot help you with number 2, but I can tell you that it is administered as an IV infusion.

All the best,

karen

Hi Mike, 

I cannot help you with number 2, but I can tell you that it is administered as an IV infusion.

All the best,

karen

Here is an answer to question 2:

Anti PD-1 treatment acts on the immune system in a very targeted way, and its action is
far more sophisticated than how ordinary chemo works.

From: http://www.hemonctoday.com/article.aspx?rid=65856
" … (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate
the balance between T cell activation, tolerance and immunopathology. In vivo studies
have shown B7-1 (CD80) is also a binding partner for PD-L1, and their interactions can
lead to bidirectional inhibitory response in T cells. PD-L1 is expressed on many tumors
including melanoma and is a component of the immune suppression by the tumor
microenvironment."

"Phase 1/2 experience of the anti-PD-1 monoclonal antibody, MDX-1106 (Medarex,
Ono-4538), in refractory or relapsed malignancies was presented at the 2009 ASCO Annual
Meeting. Clinical activity against melanoma was observed and, more importantly, no
MDX-1106 related severe adverse events were noted."

Hope this helps

Frank from Australia

Here is an answer to question 2:

Anti PD-1 treatment acts on the immune system in a very targeted way, and its action is
far more sophisticated than how ordinary chemo works.

From: http://www.hemonctoday.com/article.aspx?rid=65856
" … (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate
the balance between T cell activation, tolerance and immunopathology. In vivo studies
have shown B7-1 (CD80) is also a binding partner for PD-L1, and their interactions can
lead to bidirectional inhibitory response in T cells. PD-L1 is expressed on many tumors
including melanoma and is a component of the immune suppression by the tumor
microenvironment."

"Phase 1/2 experience of the anti-PD-1 monoclonal antibody, MDX-1106 (Medarex,
Ono-4538), in refractory or relapsed malignancies was presented at the 2009 ASCO Annual
Meeting. Clinical activity against melanoma was observed and, more importantly, no
MDX-1106 related severe adverse events were noted."

Hope this helps

Frank from Australia

Here is an answer to question 2:

Anti PD-1 treatment acts on the immune system in a very targeted way, and its action is
far more sophisticated than how ordinary chemo works.

From: http://www.hemonctoday.com/article.aspx?rid=65856
" … (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate
the balance between T cell activation, tolerance and immunopathology. In vivo studies
have shown B7-1 (CD80) is also a binding partner for PD-L1, and their interactions can
lead to bidirectional inhibitory response in T cells. PD-L1 is expressed on many tumors
including melanoma and is a component of the immune suppression by the tumor
microenvironment."

"Phase 1/2 experience of the anti-PD-1 monoclonal antibody, MDX-1106 (Medarex,
Ono-4538), in refractory or relapsed malignancies was presented at the 2009 ASCO Annual
Meeting. Clinical activity against melanoma was observed and, more importantly, no
MDX-1106 related severe adverse events were noted."

Hope this helps

Frank from Australia

2008 Article by Dr Weber.  
http://intimm.oxfordjournals.org/content/21/9/1065.full

The targeted therapies tend to work based on identifying the oncoproteins that are on the surface of tumors.

Another question (which it is to late for me to  look up now) is what is the actual delivery method of the anti-PD-1 drug into the actual tumor? versus delivery into ones body?  Is it via oxidants, bacteria or what?

2008 Article by Dr Weber.  
http://intimm.oxfordjournals.org/content/21/9/1065.full

The targeted therapies tend to work based on identifying the oncoproteins that are on the surface of tumors.

Another question (which it is to late for me to  look up now) is what is the actual delivery method of the anti-PD-1 drug into the actual tumor? versus delivery into ones body?  Is it via oxidants, bacteria or what?

2008 Article by Dr Weber.  
http://intimm.oxfordjournals.org/content/21/9/1065.full

The targeted therapies tend to work based on identifying the oncoproteins that are on the surface of tumors.

Another question (which it is to late for me to  look up now) is what is the actual delivery method of the anti-PD-1 drug into the actual tumor? versus delivery into ones body?  Is it via oxidants, bacteria or what?

It is given in an IV over about an hour followed by a saline flush to push the remainder out of the line. I have done it 15 so far…

It is given in an IV over about an hour followed by a saline flush to push the remainder out of the line. I have done it 15 so far…

It is given in an IV over about an hour followed by a saline flush to push the remainder out of the line. I have done it 15 so far…